Shares of Amarin Corporation plc (Nasdaq: AMRN)+Is+In+Play/stock_lookup.php?q=AMRN" target="_blank" rel="nofollow">AMRN) are higher early Friday as traders get the memo that the stock is "in play," on likely Vascepa NCE approval and then a potential buyout.
Reports after the close Thursday suggested that NCE approval is 'in the bag.' If this is true, attention will turn to the product launch. The company could go it alone, partner with someone, or sell the entire operation.
Recently, analysts at MKM's Partners have been clamoring that a buyout is likely and could come before the end of the year. They said AstraZeneca (NYSE: AZN) is the most logical suitor, but Pfizer, Bristol Myers, Sanofi and others could also be interested.
Shares of AMRN are up 5 percent today to $12.85.